(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.61%.
Quince Therapeutics's earnings in 2026 is -$56,979,000.On average, 8 Wall Street analysts forecast QNCX's earnings for 2026 to be -$39,561,699, with the lowest QNCX earnings forecast at -$67,825,623, and the highest QNCX earnings forecast at -$6,431,212. On average, 7 Wall Street analysts forecast QNCX's earnings for 2027 to be -$32,562,535, with the lowest QNCX earnings forecast at -$67,118,468, and the highest QNCX earnings forecast at -$1,753,967.
In 2028, QNCX is forecast to generate -$3,123,732 in earnings, with the lowest earnings forecast at -$26,192,573 and the highest earnings forecast at $21,632,259.